JP2017501177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501177A5 JP2017501177A5 JP2016541014A JP2016541014A JP2017501177A5 JP 2017501177 A5 JP2017501177 A5 JP 2017501177A5 JP 2016541014 A JP2016541014 A JP 2016541014A JP 2016541014 A JP2016541014 A JP 2016541014A JP 2017501177 A5 JP2017501177 A5 JP 2017501177A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- triazolo
- pyrimidin
- carboxamide
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 147
- 125000003545 alkoxy group Chemical group 0.000 claims description 68
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 68
- 125000005843 halogen group Chemical group 0.000 claims description 66
- 125000003282 alkyl amino group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 239000001257 hydrogen Substances 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 32
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 30
- -1 amino, phenyl Chemical group 0.000 claims description 30
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 5
- 208000024699 Chagas disease Diseases 0.000 claims description 5
- 208000004554 Leishmaniasis Diseases 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 5
- 229930183010 Amphotericin Natural products 0.000 claims description 4
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 4
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 4
- 229940009444 amphotericin Drugs 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- PFOYFBYIHCVQGB-XCCFGPONSA-N (4r,5s,6r)-2-[[(4r,5s,6r)-4-carboxy-6-[(1r)-1,2-dihydroxyethyl]-5-hydroxy-2-oxo-1,3,2$l^{5}-dioxastibinan-2-yl]oxy]-6-[(1r)-1,2-dihydroxyethyl]-5-hydroxy-2-oxo-1,3,2$l^{5}-dioxastibinane-4-carboxylic acid Chemical group O1[C@@H](C(O)=O)[C@@H](O)[C@@H]([C@H](O)CO)O[Sb]1(=O)O[Sb]1(=O)O[C@@H](C(O)=O)[C@@H](O)[C@@H]([C@H](O)CO)O1 PFOYFBYIHCVQGB-XCCFGPONSA-N 0.000 claims description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 2
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical group [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 claims description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229960004001 benznidazole Drugs 0.000 claims description 2
- 229940053382 meglumine antimonate Drugs 0.000 claims description 2
- XOGYVDXPYVPAAQ-SESJOKTNSA-M meglumine antimoniate Chemical compound O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO XOGYVDXPYVPAAQ-SESJOKTNSA-M 0.000 claims description 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003775 miltefosine Drugs 0.000 claims description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 2
- 229960001914 paromomycin Drugs 0.000 claims description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical group C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004448 pentamidine Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 2
- 229960005314 suramin Drugs 0.000 claims description 2
- VFJMWZSEQZMVTB-UHFFFAOYSA-N N-[4-fluoro-3-(6-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N2CCCC2)=N1 VFJMWZSEQZMVTB-UHFFFAOYSA-N 0.000 claims 2
- RGPFEUJUCVLECK-UHFFFAOYSA-N N-[4-fluoro-3-[6-(2-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=C(C=CC=C2)F)=N1 RGPFEUJUCVLECK-UHFFFAOYSA-N 0.000 claims 2
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 229960002644 nifurtimox Drugs 0.000 claims 2
- RJMYDSSPWRETSL-BEFAXECRSA-N (2S,4R)-4-fluoro-1-[[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]carbamoyl]pyrrolidine-2-carboxylic acid Chemical compound F[C@@H]1C[C@H](N(C1)C(NC1=CC(=C(C=C1)F)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1)=O)C(=O)O RJMYDSSPWRETSL-BEFAXECRSA-N 0.000 claims 1
- SFGVRDFCSIXHNK-SNVBAGLBSA-N (3R)-N-[3-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-3-fluoropyrrolidine-1-carboxamide Chemical compound ClC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2C[C@@H](CC2)F SFGVRDFCSIXHNK-SNVBAGLBSA-N 0.000 claims 1
- AKJACVYFLUIXNN-GFCCVEGCSA-N (3R)-N-[3-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-3-methoxypyrrolidine-1-carboxamide Chemical compound ClC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2C[C@@H](CC2)OC AKJACVYFLUIXNN-GFCCVEGCSA-N 0.000 claims 1
- QINQFYLSDQUJFV-OAHLLOKOSA-N (3R)-N-[3-[6-(3,6-dihydro-2H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-3-fluoropyrrolidine-1-carboxamide Chemical compound O1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2C[C@@H](CC2)F QINQFYLSDQUJFV-OAHLLOKOSA-N 0.000 claims 1
- BCCBAMHUCZTNET-GOSISDBHSA-N (3R)-N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-3-methoxypyrrolidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)N1C[C@@H](CC1)OC)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 BCCBAMHUCZTNET-GOSISDBHSA-N 0.000 claims 1
- GQAQMVKXMCKWNT-UHFFFAOYSA-N 3,3-difluoro-N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]azetidine-1-carboxamide Chemical compound FC1(CN(C1)C(=O)NC1=CC(=C(C=C1)F)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1)F GQAQMVKXMCKWNT-UHFFFAOYSA-N 0.000 claims 1
- DTXRJQRSZZIGKX-UHFFFAOYSA-N 3-[3-[6-(3,6-dihydro-2H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-1,1-dimethylurea Chemical compound O1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(N(C)C)=O DTXRJQRSZZIGKX-UHFFFAOYSA-N 0.000 claims 1
- FYQVCYOKOABRSI-UHFFFAOYSA-N 3-fluoro-N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]azetidine-1-carboxamide Chemical compound FC1CN(C1)C(=O)NC1=CC(=C(C=C1)F)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 FYQVCYOKOABRSI-UHFFFAOYSA-N 0.000 claims 1
- WXZFCGRYVWYYTG-UHFFFAOYSA-N GNF6702 Chemical compound O1C(C)=NC(C)=C1C(=O)NC1=CC=C(F)C(C2=NN3C=C(C=NC3=N2)C=2N=CC=CC=2)=C1 WXZFCGRYVWYYTG-UHFFFAOYSA-N 0.000 claims 1
- XQMWRLONVZQVCA-UHFFFAOYSA-N N-[2,4-difluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=CC(=C1C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1)F)NC(=O)C1=C(N=C(O1)C)C XQMWRLONVZQVCA-UHFFFAOYSA-N 0.000 claims 1
- RBNUUPWPVKPMMF-UHFFFAOYSA-N N-[2,4-difluoro-5-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C(=C1)F)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1)NC(=O)C1=C(N=C(O1)C)C RBNUUPWPVKPMMF-UHFFFAOYSA-N 0.000 claims 1
- RAYOESJRAPQPNA-UHFFFAOYSA-N N-[3-(6-bromo-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-chlorophenyl]furan-2-carboxamide Chemical compound BrC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2Cl)NC(=O)C=2OC=CC2 RAYOESJRAPQPNA-UHFFFAOYSA-N 0.000 claims 1
- WNNOVRFDLXNVJB-UHFFFAOYSA-N N-[3-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound ClC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C WNNOVRFDLXNVJB-UHFFFAOYSA-N 0.000 claims 1
- ZQWKZFGKOLZSPI-UHFFFAOYSA-N N-[3-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-2-methyl-1,3-oxazole-5-carboxamide Chemical compound ClC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=CN=C(O2)C ZQWKZFGKOLZSPI-UHFFFAOYSA-N 0.000 claims 1
- FHRLPIZDHRMMQD-UHFFFAOYSA-N N-[3-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-3,3-difluoroazetidine-1-carboxamide Chemical compound ClC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2CC(C2)(F)F FHRLPIZDHRMMQD-UHFFFAOYSA-N 0.000 claims 1
- QYCKDUAKNYAVIT-UHFFFAOYSA-N N-[3-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-3-fluoroazetidine-1-carboxamide Chemical compound ClC=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2CC(C2)F QYCKDUAKNYAVIT-UHFFFAOYSA-N 0.000 claims 1
- ZFLXEULSRFMDEX-UHFFFAOYSA-N N-[3-(6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound C1(CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C ZFLXEULSRFMDEX-UHFFFAOYSA-N 0.000 claims 1
- ZFBPPFZHUJIKNH-UHFFFAOYSA-N N-[3-[6-(1-benzyl-3,6-dihydro-2H-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound C(C1=CC=CC=C1)N1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C ZFBPPFZHUJIKNH-UHFFFAOYSA-N 0.000 claims 1
- DGHKVAQTVVNIPN-UHFFFAOYSA-N N-[3-[6-(2,5-dihydro-1H-pyrrol-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound N1CC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C DGHKVAQTVVNIPN-UHFFFAOYSA-N 0.000 claims 1
- JHMHAYJMNXQHLG-UHFFFAOYSA-N N-[3-[6-(3,3-difluoroazetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1(CN(C1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C)F JHMHAYJMNXQHLG-UHFFFAOYSA-N 0.000 claims 1
- DYZAPNHCTAAOEM-UHFFFAOYSA-N N-[3-[6-(3,6-dihydro-2H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound O1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C DYZAPNHCTAAOEM-UHFFFAOYSA-N 0.000 claims 1
- INJQSWQCBDHFGV-UHFFFAOYSA-N N-[3-[6-(3,6-dihydro-2H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-3-fluoroazetidine-1-carboxamide Chemical compound O1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2CC(C2)F INJQSWQCBDHFGV-UHFFFAOYSA-N 0.000 claims 1
- BJHZNOFPFKPMET-UHFFFAOYSA-N N-[3-[6-(3,6-dihydro-2H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]azetidine-1-carboxamide Chemical compound O1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)N2CCC2 BJHZNOFPFKPMET-UHFFFAOYSA-N 0.000 claims 1
- UQZAWLLGLJCPTI-UHFFFAOYSA-N N-[3-[6-(3,6-dihydro-2H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound O1CCC(=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2)NC(=O)C2=C(N=C(O2)C)C UQZAWLLGLJCPTI-UHFFFAOYSA-N 0.000 claims 1
- ZAPFDTJBYGSHRW-UHFFFAOYSA-N N-[3-[6-(3-chloropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound ClC=1C(=NC=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C ZAPFDTJBYGSHRW-UHFFFAOYSA-N 0.000 claims 1
- PBKDPASYHAXBEW-UHFFFAOYSA-N N-[3-[6-(5-chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound ClC=1C=C(C=NC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C PBKDPASYHAXBEW-UHFFFAOYSA-N 0.000 claims 1
- GWXKHJPBBUWKRC-UHFFFAOYSA-N N-[3-[6-(7-azabicyclo[2.2.1]hept-2-en-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound C12C(=CC(CC1)N2)C=2C=NC=1N(C2)N=C(N1)C=1C=C(C=CC1F)NC(=O)C1=C(N=C(O1)C)C GWXKHJPBBUWKRC-UHFFFAOYSA-N 0.000 claims 1
- CCRWYMXDQSVFHU-UHFFFAOYSA-N N-[3-[6-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound N1(CCC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C CCRWYMXDQSVFHU-UHFFFAOYSA-N 0.000 claims 1
- XBTIJJZSIAIOGR-UHFFFAOYSA-N N-[3-[6-(cyclopenten-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound C1(=CCCC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C XBTIJJZSIAIOGR-UHFFFAOYSA-N 0.000 claims 1
- KCSMCFBFTIHJRH-UHFFFAOYSA-N N-[3-[6-(diethylamino)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound C(C)N(C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C)CC KCSMCFBFTIHJRH-UHFFFAOYSA-N 0.000 claims 1
- MZBMHCKLGYPNMS-UHFFFAOYSA-N N-[3-[6-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound CN(C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C)C MZBMHCKLGYPNMS-UHFFFAOYSA-N 0.000 claims 1
- QCHYCCSYVQBBST-DLBZAZTESA-N N-[3-[6-[(1S,5R)-8-azabicyclo[3.2.1]oct-2-en-3-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound [C@H]12CC(=C[C@H](CC1)N2)C=2C=NC=1N(C2)N=C(N1)C=1C=C(C=CC1F)NC(=O)C1=C(N=C(O1)C)C QCHYCCSYVQBBST-DLBZAZTESA-N 0.000 claims 1
- SAQPDOGLYJCGJM-UHFFFAOYSA-N N-[3-[6-[3-(difluoromethyl)pyridin-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC(C=1C(=NC=CC1)C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C)F SAQPDOGLYJCGJM-UHFFFAOYSA-N 0.000 claims 1
- DQRJYBNALXMGQU-UHFFFAOYSA-N N-[3-[6-[ethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorophenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound C(C)N(C=1C=NC=2N(C1)N=C(N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C)C DQRJYBNALXMGQU-UHFFFAOYSA-N 0.000 claims 1
- UTZXTOGKRSSYMC-UHFFFAOYSA-N N-[4-chloro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]furan-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)NC(=O)C=1OC=CC1)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 UTZXTOGKRSSYMC-UHFFFAOYSA-N 0.000 claims 1
- WOFHYNMCCXXWTN-UHFFFAOYSA-N N-[4-chloro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]pyrrolidine-1-carboxamide Chemical compound ClC1=C(C=C(C=C1)NC(=O)N1CCCC1)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 WOFHYNMCCXXWTN-UHFFFAOYSA-N 0.000 claims 1
- JJVVJJTXSUHRJV-UHFFFAOYSA-N N-[4-fluoro-3-(6-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N2CCOCC2)=N1 JJVVJJTXSUHRJV-UHFFFAOYSA-N 0.000 claims 1
- HAZSOZXXVLAJEU-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 HAZSOZXXVLAJEU-UHFFFAOYSA-N 0.000 claims 1
- LMZMDYJLHSYMBU-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2-methyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=CN=C(O1)C)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 LMZMDYJLHSYMBU-UHFFFAOYSA-N 0.000 claims 1
- NCBJEYCGFPCYDC-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-3,3-dimethylazetidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)N1CC(C1)(C)C)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 NCBJEYCGFPCYDC-UHFFFAOYSA-N 0.000 claims 1
- QPFUZDPGJCUAIX-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-3-methylazetidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)N1CC(C1)C)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 QPFUZDPGJCUAIX-UHFFFAOYSA-N 0.000 claims 1
- IJRPXINFPLIPGD-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]azetidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)N1CCC1)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 IJRPXINFPLIPGD-UHFFFAOYSA-N 0.000 claims 1
- ZQNOIOZONWZJAU-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]cyclobutanecarboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1CCC1)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 ZQNOIOZONWZJAU-UHFFFAOYSA-N 0.000 claims 1
- COZIECYBULLICV-UHFFFAOYSA-N N-[4-fluoro-3-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]pyrrolidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)N1CCCC1)C1=NN2C(N=CC(=C2)C2=CC=CC=C2)=N1 COZIECYBULLICV-UHFFFAOYSA-N 0.000 claims 1
- JEWNWAPEGHYYFP-UHFFFAOYSA-N N-[4-fluoro-3-(6-piperazin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N2CCNCC2)=N1 JEWNWAPEGHYYFP-UHFFFAOYSA-N 0.000 claims 1
- PLPZYXLBJWNYCI-UHFFFAOYSA-N N-[4-fluoro-3-(6-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N2CCCCC2)=N1 PLPZYXLBJWNYCI-UHFFFAOYSA-N 0.000 claims 1
- ZRUSTYCFSHDJRI-UHFFFAOYSA-N N-[4-fluoro-3-(6-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C(C)C)=N1 ZRUSTYCFSHDJRI-UHFFFAOYSA-N 0.000 claims 1
- PLVQQRYVMOHPMQ-UHFFFAOYSA-N N-[4-fluoro-3-(6-pyrazin-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CN=C2)=N1 PLVQQRYVMOHPMQ-UHFFFAOYSA-N 0.000 claims 1
- KULHHHNEDOBTCH-UHFFFAOYSA-N N-[4-fluoro-3-(6-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-N,2,4-trimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)N(C(=O)C1=C(N=C(O1)C)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2)=N1 KULHHHNEDOBTCH-UHFFFAOYSA-N 0.000 claims 1
- CSUOLGWQOUDDIV-UHFFFAOYSA-N N-[4-fluoro-3-(6-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]azetidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)N1CCC1)C1=NN2C(N=CC(=C2)C2=NC=CC=C2)=N1 CSUOLGWQOUDDIV-UHFFFAOYSA-N 0.000 claims 1
- GXUOOCWPMSBNPF-UHFFFAOYSA-N N-[4-fluoro-3-(6-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NC=CC2)=N1 GXUOOCWPMSBNPF-UHFFFAOYSA-N 0.000 claims 1
- LLFLOSOPMKRYTR-UHFFFAOYSA-N N-[4-fluoro-3-(6-trimethylsilyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)[Si](C)(C)C)=N1 LLFLOSOPMKRYTR-UHFFFAOYSA-N 0.000 claims 1
- SBOJXOMKQVRXDT-UHFFFAOYSA-N N-[4-fluoro-3-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound N1=C(N=C2N1C=CC=N2)C=2C=C(C=CC2F)NC(=O)C2=C(N=C(O2)C)C SBOJXOMKQVRXDT-UHFFFAOYSA-N 0.000 claims 1
- HNKWCMPOPKNVAV-UHFFFAOYSA-N N-[4-fluoro-3-[6-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2CCN(CC2)C)=N1 HNKWCMPOPKNVAV-UHFFFAOYSA-N 0.000 claims 1
- INXXKQVWJRJERS-UHFFFAOYSA-N N-[4-fluoro-3-[6-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2CN(CCC2)C)=N1 INXXKQVWJRJERS-UHFFFAOYSA-N 0.000 claims 1
- WNBUPWYLZZWIFI-UHFFFAOYSA-N N-[4-fluoro-3-[6-(1-methylpyrazol-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NN(C=C2)C)=N1 WNBUPWYLZZWIFI-UHFFFAOYSA-N 0.000 claims 1
- MJNVJSNKZHTDAS-UHFFFAOYSA-N N-[4-fluoro-3-[6-(2,2,6,6-tetramethyl-1,3-dihydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2CC(NC(C2)(C)C)(C)C)=N1 MJNVJSNKZHTDAS-UHFFFAOYSA-N 0.000 claims 1
- JNHTXVDQFFFJIT-UHFFFAOYSA-N N-[4-fluoro-3-[6-(2,2,6,6-tetramethyl-3H-pyran-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2CC(OC(C2)(C)C)(C)C)=N1 JNHTXVDQFFFJIT-UHFFFAOYSA-N 0.000 claims 1
- HFTMAZYRAYXAFH-UHFFFAOYSA-N N-[4-fluoro-3-[6-(2-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C(=NC=CC2)OC)=N1 HFTMAZYRAYXAFH-UHFFFAOYSA-N 0.000 claims 1
- ZCQXUDATWPRWNX-UHFFFAOYSA-N N-[4-fluoro-3-[6-(2-methylpyrazol-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=CC=NN2C)=N1 ZCQXUDATWPRWNX-UHFFFAOYSA-N 0.000 claims 1
- IBFZTNBBRHSTDI-UHFFFAOYSA-N N-[4-fluoro-3-[6-(3-fluoroazetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N2CC(C2)F)=N1 IBFZTNBBRHSTDI-UHFFFAOYSA-N 0.000 claims 1
- DFEWMGPEKUHLSL-UHFFFAOYSA-N N-[4-fluoro-3-[6-(3-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2F)=N1 DFEWMGPEKUHLSL-UHFFFAOYSA-N 0.000 claims 1
- KGJBVEXBERFKNV-UHFFFAOYSA-N N-[4-fluoro-3-[6-(3-methoxypyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2OC)=N1 KGJBVEXBERFKNV-UHFFFAOYSA-N 0.000 claims 1
- GNVVPYCWVLCWKV-UHFFFAOYSA-N N-[4-fluoro-3-[6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1 GNVVPYCWVLCWKV-UHFFFAOYSA-N 0.000 claims 1
- CHZLXLROXBCGLE-UHFFFAOYSA-N N-[4-fluoro-3-[6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-N,2,4-trimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)N(C(=O)C1=C(N=C(O1)C)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1 CHZLXLROXBCGLE-UHFFFAOYSA-N 0.000 claims 1
- MQLRVDKHYWWUBA-UHFFFAOYSA-N N-[4-fluoro-3-[6-(5-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NNC2C)=N1 MQLRVDKHYWWUBA-UHFFFAOYSA-N 0.000 claims 1
- LFUDCUGGAVDJDG-UHFFFAOYSA-N N-[4-fluoro-3-[6-(5-methylpyrazin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=C(N=C2)C)=N1 LFUDCUGGAVDJDG-UHFFFAOYSA-N 0.000 claims 1
- DMVFTOAMSCOGII-UHFFFAOYSA-N N-[4-fluoro-3-[6-(6-methoxypyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC(=CC=C2)OC)=N1 DMVFTOAMSCOGII-UHFFFAOYSA-N 0.000 claims 1
- MBWHEXRVNOQODU-UHFFFAOYSA-N N-[4-fluoro-3-[6-(6-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NC(=CC2)OC)=N1 MBWHEXRVNOQODU-UHFFFAOYSA-N 0.000 claims 1
- YFLCTPSABGPJEO-UHFFFAOYSA-N N-[4-fluoro-3-[6-(6-morpholin-4-ylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NC(=CC2)N2CCOCC2)=N1 YFLCTPSABGPJEO-UHFFFAOYSA-N 0.000 claims 1
- KTDQEQUDQAGYNA-UHFFFAOYSA-N N-[4-fluoro-3-[6-(6-piperazin-1-ylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NC(=CC2)N2CCNCC2)=N1 KTDQEQUDQAGYNA-UHFFFAOYSA-N 0.000 claims 1
- ZRCOLFWDYQBQKK-UHFFFAOYSA-N N-[4-fluoro-3-[6-(6-propan-2-yloxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NC(=CC2)OC(C)C)=N1 ZRCOLFWDYQBQKK-UHFFFAOYSA-N 0.000 claims 1
- DCPWHQRTFXVURR-UHFFFAOYSA-N N-[4-fluoro-3-[6-(propan-2-ylamino)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)NC(C)C)=N1 DCPWHQRTFXVURR-UHFFFAOYSA-N 0.000 claims 1
- LHEKEDLMEMFPDY-CYBMUJFWSA-N N-[4-fluoro-3-[6-[(3R)-3-fluoropyrrolidin-1-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N2C[C@@H](CC2)F)=N1 LHEKEDLMEMFPDY-CYBMUJFWSA-N 0.000 claims 1
- FYWUYMQEKFLNOT-UHFFFAOYSA-N N-[4-fluoro-3-[6-[3-(trifluoromethyl)pyridin-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C(F)(F)F)=N1 FYWUYMQEKFLNOT-UHFFFAOYSA-N 0.000 claims 1
- KFGNAVPYMJQPTP-UHFFFAOYSA-N N-[4-fluoro-3-[6-[4-(2-morpholin-4-ylethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=CC=C(C=C2)CCN2CCOCC2)=N1 KFGNAVPYMJQPTP-UHFFFAOYSA-N 0.000 claims 1
- JPWJJCCKAOODGA-UHFFFAOYSA-N N-[4-fluoro-3-[6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C=2C=NC(=CC2)N2CCN(CC2)C)=N1 JPWJJCCKAOODGA-UHFFFAOYSA-N 0.000 claims 1
- QRKGXXNJFSGSOG-UHFFFAOYSA-N N-[4-fluoro-3-[6-[methyl(propan-2-yl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)N(C)C(C)C)=N1 QRKGXXNJFSGSOG-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 244000045947 parasite Species 0.000 description 5
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 4
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 2
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918089P | 2013-12-19 | 2013-12-19 | |
| US61/918,089 | 2013-12-19 | ||
| PCT/US2014/071077 WO2015095477A1 (en) | 2013-12-19 | 2014-12-18 | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501177A JP2017501177A (ja) | 2017-01-12 |
| JP2017501177A5 true JP2017501177A5 (enExample) | 2018-01-18 |
| JP6392352B2 JP6392352B2 (ja) | 2018-09-19 |
Family
ID=52302387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541014A Active JP6392352B2 (ja) | 2013-12-19 | 2014-12-18 | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 |
Country Status (41)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104749A1 (es) * | 2015-05-29 | 2017-08-09 | Glaxosmithkline Ip Dev Ltd | Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento |
| RS61434B1 (sr) * | 2015-08-07 | 2021-03-31 | Glaxosmithkline Ip Dev Ltd | Jedinjenja |
| US10399966B2 (en) | 2016-01-21 | 2019-09-03 | University Of Washington | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof |
| EP3601233B1 (en) | 2017-03-27 | 2024-08-14 | Hydro-Québec | Salts for use in electrolyte compositions or as electrode additives |
| JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
| EA039324B1 (ru) * | 2017-11-06 | 2022-01-13 | Новартис Аг | 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |
| TW202028208A (zh) * | 2018-10-09 | 2020-08-01 | 瑞士商諾華公司 | N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| DE3130633A1 (de) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| DE3224512A1 (de) | 1982-07-01 | 1984-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| FR2652085A1 (fr) | 1989-09-20 | 1991-03-22 | Science Organisation | Nouveau procede de synthese de derives d'oxazolopyridines. |
| DE4129603A1 (de) | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| JPH0643588A (ja) * | 1992-07-27 | 1994-02-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| DE4304650A1 (de) | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| JP3735741B2 (ja) * | 1995-11-24 | 2006-01-18 | 株式会社大塚製薬工場 | 縮環ピリミジン誘導体 |
| JP2000516611A (ja) | 1996-08-14 | 2000-12-12 | ワーナー―ランバート・コンパニー | Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体 |
| AU4499697A (en) * | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| CA2402516A1 (en) | 2000-03-20 | 2001-09-27 | Roopa Rai | Non-amidine containing protease inhibitors |
| EP1294718A2 (en) | 2000-06-14 | 2003-03-26 | Warner-Lambert Company Llc | 6,5-fused bicyclic heterocycles |
| AU2002216649A1 (en) | 2000-10-31 | 2002-05-15 | Lynn Bonham | Benzoxazole lpaat- beta inhibitors and uses thereof |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| AU2002225767A1 (en) | 2000-11-28 | 2002-06-11 | Guilford Pharmaceuticals Inc. | Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| JP4658473B2 (ja) | 2001-07-27 | 2011-03-23 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用 |
| US7488598B2 (en) | 2001-10-26 | 2009-02-10 | Cornell Center For Technology Enterprise And Commercialization | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| KR100919147B1 (ko) | 2001-11-16 | 2009-09-25 | 닛뽕 케미파 가부시키가이샤 | 크산틴 옥시다제 저해제 |
| WO2003045929A1 (en) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| BRPI0412636A (pt) * | 2003-07-30 | 2006-09-26 | S A L V A T Lab Sa | imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer |
| CA2533990A1 (en) | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| WO2005030206A1 (en) | 2003-09-24 | 2005-04-07 | Imclone Systems Incorporated | Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity |
| CA2554554A1 (en) | 2004-03-08 | 2005-09-22 | The University Of North Carolina At Chapel Hill | Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2a]pyridines as antiprotozoal agents |
| CN101087786A (zh) | 2004-12-23 | 2007-12-12 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物，它们的制备及作为药剂的应用 |
| CA2589779A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| WO2007017143A1 (en) | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents |
| US7776878B2 (en) | 2005-08-01 | 2010-08-17 | Hoffmann-La Roche Inc. | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| US20070037865A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| US7438916B2 (en) | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
| US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
| JP5054770B2 (ja) | 2006-07-11 | 2012-10-24 | デウン ファーマシューティカル カンパニー リミテッド | 新規のビアリールベンゾイミダゾール誘導体及びこれを含む医薬組成物 |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| WO2008100376A2 (en) | 2007-02-15 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Truncation variants of sirt1 and methods of use thereof |
| US20090131481A1 (en) | 2007-03-27 | 2009-05-21 | Paratek Pharmaceuticals, Inc. | Transcription Factor Modulating Compounds and Methods of Use Thereof |
| AR068072A1 (es) | 2007-04-19 | 2009-11-04 | Novartis Ag | Derivados de bencimidazoles, composiciones farmaceuticas y usos |
| US8188083B2 (en) | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| CN101802129B (zh) | 2007-10-17 | 2014-01-01 | 第一毛织株式会社 | 有机光电装置用新化合物及包括该化合物的有机光电装置 |
| RU2364597C1 (ru) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| MX2011002060A (es) | 2008-08-25 | 2011-04-05 | Irm Llc | Moduladores de la senda de hedgehog. |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| JO3156B1 (ar) * | 2009-07-09 | 2017-09-20 | Novartis Ag | ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا |
| JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
| WO2011041304A2 (en) * | 2009-09-29 | 2011-04-07 | Board Of Regents, University Of Texas System | Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase |
| EP2528893B1 (en) * | 2010-01-29 | 2018-10-10 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| US20130150351A1 (en) | 2010-06-03 | 2013-06-13 | Stanley T. Carmichael | Methods and compositions for treating a subject for central nervous system (cns) injury |
| TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| JP5999387B2 (ja) | 2011-03-25 | 2016-09-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｒｔｈ２拮抗薬としてのピラゾール化合物 |
| WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
| KR102033806B1 (ko) | 2011-11-11 | 2019-10-17 | 길리어드 아폴로, 엘엘씨 | Ａｃｃ 억제제 및 이의 용도 |
| WO2013078254A1 (en) | 2011-11-22 | 2013-05-30 | Array Biopharma Inc. | Bicyclic heteroaryl derivatives as kinase inhibitors |
| JP6049768B2 (ja) * | 2012-03-07 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | トリアゾロピラジン誘導体 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| AR091586A1 (es) | 2012-06-28 | 2015-02-11 | Fujifilm Corp | Derivado de amida o su sal como inhibidor de la produccion de colageno |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| AU2013305475B2 (en) | 2012-08-21 | 2017-10-12 | Peter Maccallum Cancer Institute | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| UY35400A (es) * | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
-
2014
- 2014-12-18 TW TW103144389A patent/TWI674263B/zh not_active IP Right Cessation
- 2014-12-18 TN TN2016000253A patent/TN2016000253A1/en unknown
- 2014-12-18 CR CR20160334A patent/CR20160334A/es unknown
- 2014-12-18 EP EP14825046.7A patent/EP3083627B1/en active Active
- 2014-12-18 CU CU2016000090A patent/CU24379B1/es unknown
- 2014-12-18 CA CA2932870A patent/CA2932870C/en active Active
- 2014-12-18 UA UAA201607112A patent/UA117046C2/uk unknown
- 2014-12-18 PE PE2016000831A patent/PE20160865A1/es active IP Right Grant
- 2014-12-18 KR KR1020167019388A patent/KR102354082B1/ko not_active Expired - Fee Related
- 2014-12-18 PT PT14825046T patent/PT3083627T/pt unknown
- 2014-12-18 NZ NZ721650A patent/NZ721650A/en not_active IP Right Cessation
- 2014-12-18 SI SI201430990T patent/SI3083627T1/sl unknown
- 2014-12-18 CN CN201480075574.3A patent/CN106029666B/zh active Active
- 2014-12-18 EA EA201691271A patent/EA030823B1/ru not_active IP Right Cessation
- 2014-12-18 MY MYPI2016702061A patent/MY175865A/en unknown
- 2014-12-18 ES ES14825046T patent/ES2701087T3/es active Active
- 2014-12-18 SG SG11201604618TA patent/SG11201604618TA/en unknown
- 2014-12-18 BR BR112016014004-4A patent/BR112016014004B1/pt active IP Right Grant
- 2014-12-18 LT LTEP14825046.7T patent/LT3083627T/lt unknown
- 2014-12-18 DK DK14825046.7T patent/DK3083627T3/da active
- 2014-12-18 RS RS20181477A patent/RS58053B1/sr unknown
- 2014-12-18 US US14/574,775 patent/US9303034B2/en active Active
- 2014-12-18 AU AU2014364565A patent/AU2014364565B2/en active Active
- 2014-12-18 JP JP2016541014A patent/JP6392352B2/ja active Active
- 2014-12-18 AP AP2016009329A patent/AP2016009329A0/en unknown
- 2014-12-18 HR HRP20182021TT patent/HRP20182021T1/hr unknown
- 2014-12-18 HU HUE14825046A patent/HUE040254T2/hu unknown
- 2014-12-18 MA MA39186A patent/MA39186A1/fr unknown
- 2014-12-18 PL PL14825046T patent/PL3083627T3/pl unknown
- 2014-12-18 WO PCT/US2014/071077 patent/WO2015095477A1/en not_active Ceased
- 2014-12-18 MX MX2016008079A patent/MX368072B/es active IP Right Grant
- 2014-12-19 UY UY0001035903A patent/UY35903A/es not_active Application Discontinuation
- 2014-12-19 AR ARP140104775A patent/AR098844A1/es active IP Right Grant
-
2016
- 2016-02-23 US US15/051,446 patent/US9700559B2/en active Active
- 2016-06-05 IL IL246034A patent/IL246034B/en active IP Right Grant
- 2016-06-09 CL CL2016001421A patent/CL2016001421A1/es unknown
- 2016-06-16 SV SV2016005226A patent/SV2016005226A/es unknown
- 2016-06-17 GT GT201600131A patent/GT201600131A/es unknown
- 2016-06-17 PH PH12016501198A patent/PH12016501198A1/en unknown
- 2016-06-29 ZA ZA2016/04415A patent/ZA201604415B/en unknown
- 2016-08-16 EC ECIEPI201667921A patent/ECSP16067921A/es unknown
-
2017
- 2017-05-19 US US15/600,183 patent/US10085989B2/en active Active
-
2018
- 2018-08-29 US US16/116,418 patent/US10596175B2/en active Active
- 2018-12-05 CY CY181101300T patent/CY1121060T1/el unknown
-
2020
- 2020-02-03 US US16/780,628 patent/US11123348B2/en active Active
-
2021
- 2021-08-10 US US17/398,852 patent/US20210369716A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501177A5 (enExample) | ||
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| US9902727B2 (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| JP2017511365A5 (enExample) | ||
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| RU2015154676A (ru) | Соединения для лечения спинальной мышечной атрофии | |
| HRP20200575T1 (hr) | Spojevi karbamata i postupci pripremanja i korištenja istih | |
| JP2014531449A5 (enExample) | ||
| US20130310340A1 (en) | Method of treating muscular degradation | |
| RU2012114846A (ru) | Соединение глицина | |
| HRP20212000T1 (hr) | Aminotriazolopiridini kao inhibitori kinaze | |
| JP2016517878A5 (enExample) | ||
| JP2016503009A5 (enExample) | ||
| JP2012501312A5 (enExample) | ||
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| JP2016523911A5 (enExample) | ||
| JP2017528515A5 (enExample) | ||
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| JP2016537384A5 (enExample) | ||
| HRP20241222T1 (hr) | Makrociklički spojevi kao agonisti sting, te postupci i njihova upotreba | |
| JP2014530197A5 (enExample) | ||
| AR076968A1 (es) | Compuestos de 1h-imidazo-(4,5-c)-quinolinona | |
| RU2018120153A (ru) | Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью | |
| JP2014511355A5 (enExample) | ||
| US20100087436A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |